Search the Newsreel

PMV Pharmaceuticals Releases Q2 2026 Financial Results

PMV Pharmaceuticals reported a narrower loss for Q2 2026, with a loss of $0.34 per share compared to $0.41 in the prior year, marking a 17.1% improvement. The precision oncology company recorded a net loss of $18.1 million as it continues to invest in …

Why Eton Pharmaceuticals Is Top of the Class Today

Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 …

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and …

Quoin Pharmaceuticals Releases Q2 2026 Financial Results

Quoin Pharmaceuticals (QNRX) announced its Q2 2026 financial results, reporting a diluted EPS of -$1.90, which is a significant improvement from the -$6.28 loss in Q2 2025. The company posted a net loss of $5.4 million for the quarter. Wall Street analysts currently have …

Price-Driven Insight from (CRBP) for Rule-Based Strategy

This article provides a price-driven insight for Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), outlining near-term and mid-term strong sentiment but a weak long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256

Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and …

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update

Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming …

Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company

Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., …

Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital …

Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector …

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds …